Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Harvard Bioscience (HBIO) Cash from Operations (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Cash from Operations for 16 consecutive years, with 96000.0 as the latest value for Q4 2025.

Quarterly Cash from Operations fell 105.57% to 96000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6729000.0 through Dec 2025, up 367.29% year-over-year, with the annual reading at 6729000.0 for FY2025, 367.29% up from the prior year.
Cash from Operations for Q4 2025 was 96000.0 at Harvard Bioscience, down from 1084000.0 in the prior quarter.
The five-year high for Cash from Operations was 4361000.0 in Q3 2023, with the low at 1986000.0 in Q1 2022.
Average Cash from Operations over 5 years is 1230550.0, with a median of 1060500.0 recorded in 2021.
Peak annual rise in Cash from Operations hit 2189.74% in 2022, while the deepest fall reached 291.51% in 2022.
Over 5 years, Cash from Operations stood at 117000.0 in 2021, then soared by 2189.74% to 2679000.0 in 2022, then soared by 60.62% to 4303000.0 in 2023, then crashed by 59.91% to 1725000.0 in 2024, then crashed by 105.57% to 96000.0 in 2025.
According to Business Quant data, Cash from Operations over the past three periods came in at 96000.0, 1084000.0, and 2755000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.